Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Adaptimmune, a UK biotech company focused on using T-cell therapy to treat cancer and infectious disease, has appointed Rafael Amado as chief medical officer and Adrian Rawcliffe as chief financial officer. 4 March 2015
Japan’s largest drugmaker Takeda Pharmaceutical has promoted Christophe Weber from representative director, president and chief operating officer to representative director, president and chief executive officer. 4 March 2015
Jeffrey Barrett has been appointed the founding director for the Centre for Therapeutic Target Validation, a public-private partnership between GlaxoSmithKline, the European Bioinformatics Institute and the Wellcome Trust Sanger Institute. 2 March 2015
The former chief executive of French pharma major Sanofi Christopher Viehbacher has been appointed to the board of directors of US R&D company PureTech. 27 February 2015
Japanese drug major Astellas Pharma is to make organizational and personnel changes in the Americas, as well as streamlining business development globally. 20 February 2015
Confirming what the media had been saying most of the week, French pharma major Sanofi late yesterday said that Olivier Brandicourt will become the firm’s chief executive, effective April 2. 20 February 2015
Kymab, a pharma company based in Cambridge, UK, focusing on monoclonal antibodies, has appointed Anne Hyland as chief financial officer. 19 February 2015
Israel-based Immune Pharmaceuticals has appointed Paul Nadler as acting executive vice president of research and development, and chief medical officer. 9 February 2015
Autologous T-cell therapy product specialist Kite Pharma has appointed Salah Kivlighn as vice president of marketing and Anthony Polverino as vice president of research. 4 February 2015
Swiss pharma company Santhera has expanded its leadership team, appointing existing senior staff members Nicholas Coppard as senior vice president head of development, Günther Metz as senior vice president business development, and Oliver Strub, general counsel and secretary to the board. 2 February 2015
US biotech major Gilead Sciences has promoted Andrew Cheng to executive vice president of HIV therapeutics and development operations, and Taiyin Yang to executive vice president of pharmaceutical development and manufacturing. 29 January 2015
Switzerland-headquartered Ferring Pharmaceuticals has appointed Pascal Danglas as executive vice president and chief medical officer, and Per Falk has been appointed executive vice president and chief scientific officer. 28 January 2015